Effective combination antiretroviral therapy (cART) has increased the life span of HIV+ individuals1–3 and can successfully decrease viral load to low or undetectable levels.4,5 Although effective in reducing plasma viral load, chronic immune activation and inflammation can persist leading to non-AIDS morbidities, including cardiovascular disease (CVD).6 HIV+ individuals on cART have elevated levels of soluble CD14 (sCD14), C-reactive protein, tumor necrosis factor (TNF) α, and soluble CD163 (sCD163) that are myeloid derived and markers of activated monocytes and macrophages.7 Elite controllers who have never been on cART also have elevated plasma sCD163, activated monocytes/macrophages, and CVD, despite low-level viremia.8–10 Thus, with chronic HIV infection, activated monocytes and macrophages demonstrated by elevated sCD14 and sCD163 correlate with CVD, and with increased aortic macrophage inflammation underscoring their role in chronic immune activation with low-level plasma virus.
HIV+ individuals have increased risk of CVD compared with the general population.11,12 Growing evidence suggests that chronic immune activation and inflammation are a cause for increased CVD risk.13,14 HIV+ individuals have increased percentages of activated nonclassical (CD14+CD16++) and intermediate (CD14++CD16+) monocytes as do non–HIV-infected individuals with CVD.15 Using Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging, we have shown that increased arterial inflammation in the ascending aorta correlates with increased plasma sCD163.16 Similarly, monocyte activation markers sCD163, sCD14, and CCL2 are elevated in HIV+ individuals and associated with atherosclerosis.17
Monocytes and macrophages have been demonstrated to play roles in the development of atherosclerosis, vascular calcification, and myocarditis. Macrophages secrete TNF-α and transforming growth factor beta, which can enhance calcification in vitro.18 Macrophages are associated with calcium deposits in carotid plaques,19 and longitudinal studies provide evidence that inflammation precedes such calcification.20,21 In the heart, macrophages secrete pro-inflammatory and pro-fibrotic factors, which correlate with the extent of fibrosis.22 Unpublished data from our laboratory showed that increased macrophage accumulation in the aorta with HIV infection and plasma sCD163 correlate with increased aortic intima–media thickness. Using a simian immunodeficiency virus (SIV)–infected CD8+ T-lymphocyte depletion model of rapid and consistent AIDS, we found that macrophage infiltration of cardiac parenchymal tissue correlates with increased cardiac fibrosis.23 Blocking monocyte/macrophage traffic to the heart, using an anti-α4 antibody, decreased macrophage accumulation in cardiac tissues and correlated with decreased cardiac fibrosis.24 These results suggest that targeting macrophage accumulation can decrease HIV-associated cardiovascular inflammation and decrease HIV-associated CVD.
Few therapies exist that directly target macrophages and residual immune activation in conjunction with cART in HIV infection.6 Glucocorticoid treatment of SIV-infected animals depleted pro-inflammatory and pro-thrombic CD14+CD16++ monocytes.25 Minocycline, a tetracycline antibiotic that prevents the development of SIV encephalitis,26,27 decreased activated monocytes and monocyte/macrophage inflammation in lymph nodes.28 Minocycline treatment in humans did not decrease HIV-RNA in cerebrospinal fluid or decrease cognitive impairment but has not been tested in HIV-associated CVD.29–31 SIV-infected monkeys treated with a CCR5 inhibitor maraviroc had decreased CD163 expression on macrophages in the myocardium32 and in humans; maraviroc in conjunction with effective cART decreased vascular cell adhesion molecule-1 suggesting a possible mechanism to inhibit monocyte/macrophage traffic to the heart.33 More recently, a clinical trial using low-dose methotrexate treatment to reduce macrophage-mediated inflammation has been initiated (NCT01949116).
Methylglyoxal-bis-guanylhydrazone (MGBG) is a polyamine biosynthesis inhibitor that inhibits S-adenosine methionine decarboxylase, resulting in decreased intracellular concentrations of spermine and spermidine in monocytes/macrophages.34,35 Polyamines are necessary for macrophage activation, proliferation, and differentiation, suggesting MGBG might be useful in targeting macrophages to alleviate macrophage-mediated diseases associated with HIV infection.36,37 Previously, MGBG administered intravenously was used to treat HIV-associated lymphomas38 but was discontinued due in part to gastrointestine-associated toxicity.39 More recently, we have studied the MGBG formulated for oral administration. Initial studies showed that MGBG inhibited HIV-p24 expression and DNA integration in human monocytes/macrophages in vitro without cell-associated toxicities.40 Furthermore, we found that MGBG is taken up and concentrated in macrophages, but not by T lymphocytes. This is potentially important because most ART agents target T lymphocytes and have limited uptake and effect on macrophages that are more resistant to ART agents41
We have used a CD8+ T-lymphocyte depletion model of rapid AIDS with consistent central nervous system and cardiac pathology and found that increased macrophage accumulation in cardiac tissues and vessels leads to cardiac fibrosis and cardiomyocyte injury.23 The current study used 19 SIV-infected CD8+ lymphocyte-depleted rhesus macaques and 6 uninfected controls to examine if oral administration of MGBG decreased macrophage inflammation in the aorta, carotid artery, and left ventricle (cardiac tissue). Additionally, we determined if decreased cardiac inflammation decreased carotid artery intima–media thickness (cIMT) and cardiac fibrosis. We found that MGBG treatment significantly decreased macrophage-associated inflammation and fibrosis in cardiac tissues to levels found in uninfected animals. Compared with SIV-infected placebo controls, MGBG treatment resulted in a trend toward decreased inflammation in the carotid artery and a significantly decreased cIMT. These results suggest that MGBG directly targeting monocytes/macrophages with ART could reduce HIV-associated CVD.
All animals used in this study were handled in strict accordance with the American Association for Accreditation of Laboratory Animal Care with the approval of the Institutional Animal Care and Use Committee of Harvard University and housed at the New England Primate Research Center (Southborough, MA). The New England Primate Research Center Protocol Number for this study was 04420, and the Animal Welfare Assurance Number was A3431-01. When control animals developed clinical symptoms consistent with the development of AIDS, they and their corresponding MGBG-treated cohorts were anesthetized with ketamine–HCl and euthanized by an intravenous pentobarbital overdose and exsanguinated. Animals were killed on the basis of the following guidelines for euthanasia of SIV-infected rhesus macaques: (1) weight loss >15% in 2 weeks, 30% body weight in 2 months, or 25% overall; (2) documented opportunistic infection; (3) persistent anorexia >3–5 days without explicable cause; (4) severe intractable diarrhea (ie, nonresponsive to standard treatment and results in dehydration and debilitation of the animal); (5) progressive neurological signs (ie, instability on the perch bar, depression, head tilt, nystagmus, ataxia, stupor, or depression); (6) significant cardiac and/or pulmonary signs (ie, dyspnea, open-mouthed breathing, or severe, previously unrecognized cardiac murmur, especially if resulting in pulmonary edema); (7) persistent leukopenia; (8) progressive or persistent anemia; (9) signs of progressive immunosuppressive disease; (10) body condition score >1.5/5 with weight loss; or (11) any other serious illness. The development of simian AIDS was determined postmortem by the presence of opportunistic infections and tumors and included the development of SIV giant cell pneumonia, cytomegalovirus pneumonia, SIV encephalitis with giant cells, pneumocystis carinii, and lymphoma (Table 1).
Animals, SIV Infection, CD8+ T-Lymphocyte Depletion, MGBG Treatment
Twenty-five animals were used in this study. Six animals were uninfected controls and 19 animals SIV infected and CD8 lymphocyte depleted. Animals were infected with the SIVmac251 viral swarm provided by Dr. Ron Desroisiers. Of these, 11 received MGBG (30 mg/kg) (provided by Pathologica, LLC; formulated as syrup by Wedgewood Pharmacy, Swedesboro, NJ) orally, once daily beginning at 21 days postinfection (dpi), when significant central nervous system and cardiovascular inflammation are known to occur in this model.24,42 Eight received oral placebo-syrup control at the same time point. We had determined in previous pilot studies that an effective dose of 0.7 μM MGBG in plasma and tissues is reached in animals receiving a daily oral dose of 30 mg/kg.40 Infected animals receiving MGBG or placebo were assigned to one of 6 groups with at least one placebo control per group. Six uninfected animals were group 1. Animals in each group were killed at 49 dpi (group 2), when placebo controls developed AIDS (groups 3–6), or at the end of the study (84 days) (group 7) (Table 1).
Assessment of Cardiovascular Pathology
After exsanguination, a full SIV necropsy was performed and major organs were collected in 10% neutral-buffered formalin, embedded in paraffin, and sectioned at 5 μm. Sections of the carotid artery, aorta, and left ventricle (cardiac tissue) were stained with hematoxylin and eosin (H&E) and graded blindly by a veterinary pathologist. The carotid artery and aorta were assessed based on 2 criteria: inflammation and carotid artery or aortic degeneration. Degeneration of the carotid artery or aorta was based on the alignment of smooth muscle fibers in the tunica intima. Cardiac tissues were assessed based on the degree of inflammation, fibrosis, and cardiomyocyte degeneration. Sections were graded for each category based on the degree of change in cardiac tissues and scored as either having no significant findings or being mild, moderate, or severe. Data are presented as percentage of animals per treatment group with the corresponding level of inflammation, fibrosis, and cardiomyocyte degeneration.
Numbers of macrophages in the carotid artery (n = 11 MGBG treated, n = 8 placebo) and left ventricle (cardiac tissue) (n = 11 MGBG treated, n = 8 placebo, n = 6 SIV negative) were assessed using immunohistochemistry and cell counting as previously described.24 Formalin-fixed, paraffin-embedded sections of carotid artery and cardiac tissue were deparaffinized in xylenes and rehydrated in graded ethanols, followed by incubation with peroxidase block (Dako) for 5 minutes. Sections were incubated with serum-free protein block (Dako) for 30 minutes and then incubated with antibodies against CD163+, CD68+, CD206+, MAC387+ macrophage markers, and CD3+ T lymphocytes for 1 hour at room temperature or overnight at 4°C. Tissue sections were rinsed and incubated with an anti-mouse secondary antibody conjugated to horseradish peroxidase (Dako). The reaction product was visualized using 3, 3′-diaminobenzidine tetrahydrochloride (Dako). The average number of immune-positive macrophages per square millimeter plus or minus the standard error of the mean (SEM) was determined by counting the number of positive macrophages from 20 nonoverlapping ×200 fields of view (field area = 0.148 mm2) per section, using a Zeiss Axio Imager M1 microscope with Plan-Apochromat ×20/0.8 Korr objectives (Carl Zeiss Microimaging Inc., Thornwood, NY).
Measurement of cIMT
Sections of carotid artery were deparaffinized and rehydrated in xylenes and graded ethanol, followed by staining with a Verhoeff Van Gieson elastic stain (Sigma; St. Louis, MS) to differentiate the intima, media, and adventitia of the carotid artery wall.43 The cIMT was measured optically using ImageJ Analysis Software for 10 nonoverlapping fields of view per section. Data were expressed as the average cIMT plus or minus the SEM.
Measurement of Cardiac Fibrosis
Cardiac tissues were stained using a modified Massons Trichrome (Newcomer Supply, Middleton, WI) and the percentage of collagen per tissue area.44,45 The percent collagen (blue dye) per tissue area was determined using ImageJ Analysis Software from 20 nonoverlapping ×200 fields of view (field area = 0.148 mm2). Data were expressed as the average percent collagen per tissue area plus or minus the SEM.
In Situ Hybridization for SIV-RNA
In situ hybridization for SIV-RNA was performed using digoxigenin-labeled antisense riboprobes from Lofstrand Labs (Gaithersburg, MD), as previously described.46 Formalin-fixed, paraffin-embedded sections of carotid artery and cardiac tissues were deparaffinized and rehydrated in xylenes and graded ethanols. Sections were treated with antigen unmasking solution (Vector Labs, Burlingame, CA) for 20 minutes at high heat, washed, and prehybridized at 45°C for 1 hour with prehybridization buffer containing denatured herring sperm DNA and yeast transfer RNA at concentrations of 10 mg/mL. Digoxigenin-labeled probes (10 ng/mL) were diluted in hybridization buffer and hybridized overnight at 45°C. After stringency washes with decreasing concentrations of saline-sodium citrate (SSC) buffer, sections were blocked with a 1% blocking solution (Roche Diagnostics; Indianapolis, IN) for 30 minutes. Digoxigenin-labeled probes were detected with nitro blue tetrazolium chloride/ 5-Bromo-4-chloro-3-indolyl phosphate (Roche Diagnostics) with levamisole (Dako; Santa Clara, CA) to inhibit alkaline phosphatases. The nitro blue tetrazolium chloride/ 5-Bromo-4-chloro-3-indolyl phosphate substrate produces a visible blue reaction product.
Plasma SIV-RNA was quantified using real-time polymerase chain reaction for all animals used in this study, as previously described.47 Five hundred microliters of EDTA plasma was collected, and SIV virions were pelleted by centrifugation at 20,000g for 1 hour. The threshold sensitivity was 100 copy Eq/mL, with an average interassay coefficient variation of less than 25%.
Statistical analyses were done using Prism version 5.0 (Graphpad Software Inc., San Diego, CA). For the carotid artery, comparisons of the mean number of macrophages per square millimeter and cIMT were made between SIV-infected placebo controls and SIV-infected MGBG-treated animals using a nonparametric Mann–Whitney t test with significance accepted at P <0.05. For cardiac tissues, comparisons of the mean number of macrophages per square millimeter and the percent collagen per tissue area were made between uninfected animals, SIV-infected placebo controls, and SIV-infected MGBG-treated animals using analysis of variance. If the analysis of variance was significant (P < 0.05), a post hoc nonparametric Mann–Whitney t test was performed. A Spearman rank correlation analysis was used to determine if changes in cIMT and the percent collagen per total tissue area correlated with decreased macrophage numbers in the carotid artery and cardiac tissues of MGBG-treated animals. A Fisher exact test was used to categorically and numerically compare the degree of cardiac and cardiac vessel inflammation, fibrosis, and degeneration as assessed by a veterinary pathologist on H&E tissue sections.
MGBG Treatment Resulted in a Trend Toward Decreased Cardiovascular Pathology in SIV-Infected Rhesus Macaques
Aorta and Carotid Artery
Cardiovascular pathology was assessed blindly by a veterinary pathologist using H&E-stained tissue sections. The aorta and carotid artery were graded and the degree of inflammation, carotid artery degeneration, and cIMT scored. Neither the MGBG-treated nor placebo control animals had significant findings in the aorta. MGBG-treated animals had decreased inflammation in the carotid artery where 5 of 9 (55%) MGBG-treated animals had no inflammation compared with 2 of 6 (33%) placebo controls. Four of the 9 (44%) MGBG and 4 of the 6 (66%) placebo controls had mild carotid artery inflammation. Six of the 9 (66%) MGBG-treated animals had no significant carotid artery degeneration compared with 3 of 6 placebo controls (50%). cIMT was noted in only 1 of 9 (11%) MGBG-treated animals compared with 3 of 6 (50%) placebo controls.
Cardiac tissues (left ventricle) were scored blindly by a veterinary pathologist based on inflammation, fibrosis, and cardiomyocyte degeneration using the same criteria described above. MGBG treatment resulted in a frequency and severity of inflammation in cardiac tissues. Five of 11 (45%) MGBG-treated animals had no inflammation, whereas placebo controls had either mild (7 of 8, 87%) or moderate (1 of 8, 13%) inflammation. There was no cardiac fibrosis in 7 of 11 (63%) MGBG-treated animals, and 2 of 8 (25%) placebo controls had cardiac fibrosis. Four of 11 (37%) MGBG-treated animals had mild fibrosis, and 6 of 8 (75%) remaining placebo controls had mild to moderate fibrosis. Five of 11 (45%) MGBG-treated animals had no cardiomyocyte degeneration compared with only 1 of 8 (13%) of the placebo control animals, suggesting that MGBG decreased the frequency of cardiomyocyte degeneration. A Fisher exact statistical analysis was used to categorically and numerically compare MGBG treated versus controls with no significant findings versus mild and moderate aortic, carotid artery, and cardiac tissue and the degree of inflammation, fibrosis, or cardiomyocyte damage. We did not find significant categorical differences between groups. This can be because of the small sample size and variation and the results being a relatively nonsensitive comparison between H and E tissue sections. Further comparisons using cIMT measurements and immunohistochemical analysis and the measurement of the number of macrophages and amount of collagen deposition (fibrosis) are presented below.
MGBG Decreases Macrophage Inflammation in the Carotid Artery and Cardiac Tissue in SIV-Infected Rhesus Macaques
MGBG treatment resulted in a trend of decreased macrophage numbers in the carotid artery compared with placebo controls. There was 2.19-fold (CD163+), 1.86-fold (CD68+), 2.12-fold (MAC387+), and 2.31-fold (CD206) decreases in the numbers of macrophages in the carotid artery of MGBG-treated animals compared with placebo controls (Fig. 1A). There were no differences between the numbers of CD3+ T lymphocytes in the carotid artery in placebo controls compared with MGBG-treated animals (data now shown). MGBG treatment significantly decreased cardiac tissue macrophages compared with placebo controls. There was significant 2.07-fold (CD163+), 1.61-fold (CD68+), 1.95-fold (MAC387+), and 1.62-fold (CD206+) decreases in numbers of macrophages in cardiac tissues of MGBG-treated animals (Fig. 1B). Similar to the carotid artery, there was no difference in numbers of CD3+ T lymphocytes in cardiac tissues of placebo controls and treated animals. There were significantly increased numbers of macrophages in placebo controls compared with uninfected animals. The numbers of CD163+, MAC387+, and CD206+ macrophages in cardiac tissues of MGBG-treated animals were similar to the numbers of the same macrophages in uninfected animals (Fig. 1B).
MGBG Treatment Results in a Reduction of cIMT
MGBG treatment resulted in a significant 1.49-fold decrease of cIMT compared with placebo controls. The average cIMT for placebo controls was 0.41 ± 0.05 mm (n = 6) compared with 0.28 ± 0.02 mm for MGBG-treated animals (n = 9) (Fig. 2A, B). Spearman rank correlation analysis of tissues from placebo controls and MGBG-treated animals demonstrated a positive correlation between increased numbers of CD68+ (r = 0.52, P < 0.05), CD206+, and MAC387+ (r = 0.42, P < 0.05) macrophages present in the carotid artery and increased cIMT. There was no correlation between the number of CD163+ macrophages and increased cIMT (Fig. 2C).
MGBG Treatment Results in Decreased Cardiac Fibrosis in SIV-Infected Rhesus Macaques
There was a significant 2.05-fold decrease in the percent collagen per tissue area in MGBG-treated animals compared with placebo controls. The average percent collagen per tissue area for MGBG-treated animals was 5.79% ± 0.67% (n = 11) compared with 11.85% ± 0.98% for placebo controls (n = 8) (Fig. 3). SIV-negative animals had a mean percent collagen per tissue area of 6.74% ± 1.91% (n = 6). Placebo control animals had a significant 1.76-fold increase in the percent collagen per tissue area compared with uninfected animals. MGBG-treated animals showed no significant differences in the percent collagen per tissue area compared with uninfected animals. Spearman rank analysis of tissues from uninfected placebo controls and MGBG-treated animals demonstrated positive correlations between increased numbers of CD163+ (r = 0.69, P < 0.01), CD68+ (r = 0.63, P < 0.05), CD206+ (r = 0.54, P < 0.01), and MAC387+ (r = 0.53, P < 0.05) macrophages in cardiac tissues and increased fibrosis in cardiac tissues (Fig. 3C).
In Situ Hybridization for SIV-RNA
We did not find SIV-RNA or SIV-p28+ cells in the carotid artery or cardiac tissues of SIV-infected placebo controls or MGBG-treated animals, consistent with previous findings.23 Viral loads in all animals peaked at 8 dpi and remained elevated in MGBG-treated animals or placebo controls (data not shown). There were no statistically significant differences in plasma viral load in the MGBG-treated versus placebo-treated animals (data not shown).
With effective cART, mortality because of AIDS-related causes has decreased2,48; however, secondary comorbidities have increased.3 Although cART decreases plasma virus to low or undetectable levels, chronic immune activation that potentially drives the progression of CVD persists.49 Statins, which are likely to have a mild immune-suppressive effect on myeloid cells,50 have been used successfully to decrease CVD with HIV infection.51–53 Two studies used rosuvastatin in uninfected individuals,51 and HIV+ individuals on cART with a moderate cardiovascular risk52 found a reduced rate of cIMT progression. Additionally, atorvastatin reduced noncalcified plaque volume and high-risk coronary plaque features (positive remodeling and low attenuation of plaques) among HIV+ individuals with arterial inflammation.53 Statins do not directly target macrophages that are key players in HIV- and SIV-associated CVD54–56 and myocarditis,57,58 and to date, few therapies target them.
We and others have shown that markers of immune activation, sCD14 and sCD163,59 and not traditional risk factors of CVD are associated with atherosclerotic plaques with HIV, suggesting that chronic immune activation with HIV infection plays a role in the development of HIV-associated CVD. Increased sCD1460 and monocyte chemoattractant protein 1 (MCP-1) and TNF-α61 are also associated with increased coronary artery calcium, a marker of coronary atherosclerosis. Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging showed that with HIV infection, there is increased arterial inflammation in the ascending aorta that correlated with levels of sCD16316 and an increase in high-risk plaque morphology.62 sCD163 made by activated monocytes and macrophages also was associated with noncalcified plaques in HIV+ individuals.59 High-risk noncalcified plaques tend to have large necrotic lipid-rich cores and increased macrophage numbers compared with stable plaques.54 HIV elite controllers, who control viremia, have elevated myeloid markers of immune activation8,63 and an increased prevalence of noncalcified coronary plaques further suggesting a link between monocyte/macrophage activation and HIV-associated CVD.10
Previously, we have shown that the SIV-infected CD8+ T-lymphocyte depletion model of rapid AIDS in rhesus macaques can be used to study the effects of SIV on the development of cardiac fibrosis.23 Using this model, we found that directly blocking macrophage traffic to the heart, using an anti-α4 antibody, decreased overall cardiac pathology, macrophage inflammation, and cardiac fibrosis.24 The anti-α4 antibody is less useful in the long term in HIV+ individuals because of the potential emergence of JC virus infection with long-term usage seen in patients with Multiple Sclerosis (MS) and Crohns.64,65 In the current study, we examined the effects of an oral formulation of MGBG that is specifically taken up by and concentrated in monocytes/macrophages40 and not CD4+ T lymphocytes. We have recently demonstrated that MGBG in vitro inhibits HIV integration and replication.40 Importantly, in this study, MGBG was selectively taken up by monocytes/macrophages and not T lymphocytes. We have also found that MGBG treatment results in the downregulation of CD16 on CD14+CD16+ monocytes in vitro and decreased osteopontin expression by macrophages [using gene array and immunohistochemistry (data not shown)]. In the current study, we investigated the effects of oral administration of MGBG on SIV-associated cardiovascular inflammation in the carotid artery and heart, cIMT, and cardiac fibrosis. Animal groups consisting of placebo and MGBG-treated animals were killed early, when placebo controls developed AIDS, or at study endpoint.
We found a trend of decreased inflammation in carotid arteries of MGBG-treated animals compared with placebo controls and a significant decrease in the cIMT. cIMT, a marker of atherosclerosis and subclinical CVD,66–68 is associated with myocardial infarction and stroke.69,70 cIMT increases more rapidly in HIV+ individuals compared with age-matched control individuals71,72 and is associated with a low CD4+ T-lymphocyte count (<200 cells/mm3).73 A limitation of the current study is not having carotid arteries from uninfected animals to compare with MGBG-treated animals. It is interesting to note in the current study that 7 of the 11 MGBG-treated animals did not develop AIDS. This is of significance especially considering that MGBG is not taken up by CD4+ T lymphocytes and therefore likely has its effect more directly on macrophages underscoring their importance, in this model, on the development of AIDS. We further note that CVD with HIV or SIV infection does not seem only to be dependent on the development of AIDS. Lastly, although we have found in preliminary studies that MGBG treatment can result in decreased CD16 expression on CD14+ CD16+ monocytes, we did not find differences in the percentage of monocytes expressing CD16 in the animals in the current study until necropsy (data not shown).
MGBG treatment decreased macrophage inflammation in cardiac tissues and cardiac fibrosis compared with placebo controls. Cardiac inflammation and fibrosis in MGBG-treated animals were similar to levels seen in uninfected animals. We did not find any effect of MGBG on the number of CD3+ T lymphocytes present in cardiac tissues consistent with our findings that MGBG is selectively taken up and concentrated in monocytes and macrophages, and not T lymphocytes.40 We have previously shown in our rapid AIDS model that the accumulation of macrophages, and not T lymphocytes or viral-infected cells, best correlates with cardiac fibrosis and cardiomyocyte damage.23 Plasma viral loads for all placebo and MGBG-treated animals in this study were similar as these animals were CD8+ T-lymphocyte depleted. We did not find SIV-RNA+ cells in the hearts of our monkeys, a result that is consistent with previous reports of low or scattered SIV- and HIV-infected macrophages in cardiac tissues.74,75 Together, these data underscore the role of macrophages in the development of SIV-associated CVD. Targeting macrophages directly might be a possible way to diminish inflammation in the heart and cardiac fibrosis. Although the incidence of cardiac fibrosis has declined in the cART era among HIV+ individuals76,77 when studied recently, it is still prevalent among HIV+ individuals.78,79 Although some animals in this study that received MGBG developed AIDS, others receiving the drug did not. However, there were no differences in the levels of fibrosis and cIMT in MGBG-treated animals with and without AIDS, suggesting that the development of AIDS alone is not the sole cause of CVD, adding evidence that chronic inflammation with SIV and HIV infection likely plays a more central role.
In this study, we examined the effects MGBG on SIV-associated cardiovascular inflammation and cardiac fibrosis by directly targeting macrophages. Animals receiving daily doses of MGBG showed decreased inflammation in the carotid artery and cardiac tissue when compared with placebo controls. MGBG treatment also prevented an increase in cIMT and cardiac fibrosis that remained at levels similar to SIV-negative animals. These data suggest that therapies designed to target chronic inflammation and immune activation seen with HIV infection could be used as adjunctive therapies to cART to alleviate HIV-associated CVD.
The authors would like to thank Wedgwood Pharmacy for formulating MGBG and placebo. They also thank the veterinary staff at the New England Primate Research Center for animal care, pathology residents, and staff for assisting with necropsies and tissue collection.
1. Coquet I, Pavie J, Palmer P, et al. Survival trends in critically ill HIV
-infected patients in the highly active antiretroviral therapy era. Crit Care. 2010;14:R107.
2. Landay A, Miller CJ, Baker JV, et al. Adjudicated morbidity and mortality outcomes by age among individuals with HIV
infection on suppressive antiretroviral therapy. PLoS One. 2014;9:e95061.
3. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV
-infected persons the Swiss HIV
cohort study. Clin Infect Dis. 2011;53:1130–1139.
4. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV
-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3:e46.
5. French MA, King MS, Tschampa JM, et al. Serum immune activation markers are persistently increased in patients with HIV
infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200:1212–1215.
6. Deeks SG. HIV
, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
7. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV
suppression on circulating markers of inflammation
and immune activation. AIDS. 2015;29:463–471.
8. Li JZ, Arnold KB, Lo J, et al. Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis. 2014;2:ofu117.
9. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV
type 1-infected elite controllers. J Infect Dis. 2014;209:931–939.
10. Pereyra F, Lo J, Triant V, et al. Increased coronary atherosclerosis and immune activation in HIV
-1 elite controllers. AIDS. 2012;26:2409–2415.
11. Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular
mortality for HIV
-infected adults in the United States: 1999–2013. Am J Cardiol. 2016;117:214–220.
12. Petoumenos K, Reiss P, Ryom L, et al. Increased risk of cardiovascular
disease (CVD) with age in HIV
-positive men: a comparison of the D: a:D CVD risk equation and general population CVD risk equations. HIV
13. Stein JH, Hsue PY. Inflammation
, immune activation, and CVD risk in individuals with HIV
infection. JAMA. 2012;308:405–406.
14. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV
infection. PLoS Med. 2008;5:e203.
15. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV
-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012;120:4599–4608.
16. Subramanian S, Tawakol A, Abbara S, et al. Arterial inflammation
in patients with HIV
. JAMA. 2012;308:379–386.
17. McKibben RA, Margolick JB, Grinspoon S, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV
. Infect J Infect Dis. 2015;211:1219–1228.
18. Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650–655.
19. Jeziorska M, McCollum C, Woolley DE. Calcification in atherosclerotic plaque of human carotid arteries: associations with mast cells and macrophages. J Pathol. 1998;185:10–17.
20. Abdelbaky A, Corsini E, Figueroa AL, et al. Early aortic valve inflammation
precedes calcification: a longitudinal FDG-PET/CT study. Atherosclerosis. 2015;238:165–172.
21. Abdelbaky A, Corsini E, Figueroa AL, et al. Focal arterial inflammation
precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6:747–754.
22. Timonen P, Magga J, Risteli J, et al. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy. Int J Cardiol. 2008;124:293–300.
23. Walker JA, Sulciner ML, Nowicki KD, et al. Elevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis. AIDS Res Hum Retroviruses. 2014;30:685–694.
24. Walker JA, Beck GA, Campbell JH, et al. Anti-alpha4 integrin antibody blocks monocyte/macrophage traffic to the heart and decreases cardiac pathology in a SIV
infection model of AIDS. J Am Heart Assoc. 2015;4:e001932.
25. Moniuszko M, Liyanage NPM, Doster MN, et al. Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++Monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses. 2015;31:115–126.
26. Ratai EM, Bombardier JP, Joo CG, et al. Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One. 2010;5:e10523.
27. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005;293:2003–2011.
28. Campbell JH, Burdo TH, Autissier P, et al. Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV
neuroAIDS. PLoS One. 2011;6:e18688.
29. Ho EL, Spudich SS, Lee E, et al. Minocycline fails to modulate cerebrospinal fluid HIV
infection or immune activation in chronic untreated HIV
-1 infection: results of a pilot study. AIDS Res Ther. 2011;8:17.
30. Nakasujja N, Miyahara S, Evans S, et al. Randomized trial of minocycline in the treatment of HIV
-associated cognitive impairment. Neurology. 2013;80:196–202.
31. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV
-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77:1135–1142.
32. Kelly KM, Tocchetti CG, Lyashkov A, et al. CCR5 inhibition prevents cardiac dysfunction in the SIV
/Macaque model of HIV
. J Am Heart Assoc. 2014;3:e000874.
33. Francisci D, Falcinelli E, Baroncelli S, et al. Potential anti-inflammatory effects of maraviroc in HIV
-positive patients: a pilot study of inflammation
, endothelial dysfunction, and coagulation markers. Scand J Infect Dis. 2014;46:466–470.
34. Corti A, Dave C, Williams-Ashman HG, et al. Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J. 1974;139:351–357.
35. Williams-Ashman HG, Schenone A. Methyl glyoxal bis(guanylhydrazone) as a potent inhibitor of mammalian and yeast S-adenosylmethionine decarboxylases. Biochem Biophys Res Commun. 1972;46:288–295.
36. Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61:880–894.
37. Janne J, Holtta E, Kallio A, et al. Role of polyamines and their antimetabolites in clinical medicine. Spec Top Endocrinol Metab. 1983;5:227–293.
38. Tulpule A, Espina B, Pedro Santabarbara AB, et al. Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs. 2004;22:63–68.
39. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4:781–792.
40. Jin X, McGrath MS, Xu H. Inhibition of HIV
expression and integration in macrophages by methylglyoxal-bis-guanylhydrazone
. J Virol. 2015;89:11176–11189.
41. Gavegnano C, Detorio MA, Bassit L, et al. Cellular pharmacology and potency of HIV
-1 nucleoside analogs in primary human macrophages. Antimicrob Agents Chemother. 2013;57:1262–1269.
42. Soulas C, Conerly C, Kim WK, et al. Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV
encephalitic lesion formation. Am J Pathol. 2011;178:2121–2135.
43. Deopukari R, Dixit A. The study of age related changes in coronary arteries and its relevance to the atherosclerosis. J Anat Soc India. 2010;59:192–196.
44. Brower GL, Gardner JD, Forman MF, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg. 2006;30:604–610.
45. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291–299.
46. Williams K, Schwartz A, Corey S, et al. Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis. Am J Pathol. 2002;161:575–585.
47. Lifson JD, Rossio JL, Piatak M Jr, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol. 2001;75:10187–10199.
48. Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV
-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58:1312–1321.
49. Beltran LM, Rubio-Navarro A, Amaro-Villalobos JM, et al. Influence of immune activation and inflammatory response on cardiovascular
risk associated with the human immunodeficiency virus. Vasc Health Risk Manag. 2015;11:35–48.
50. Yadav A, Betts MR, Collman RG. Statin modulation of monocyte phenotype and function: implications for HIV
-1-associated neurocognitive disorders. J Neurovirol. 2016;2:584–596.
51. Crouse JR III, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344–1353.
52. Calza L, Manfredi R, Colangeli V, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV
type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular
risk. AIDS Res Hum Retroviruses. 2013;29:547–556.
53. Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV
-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV
54. Tahara N, Mukherjee J, de Haas HJ, et al. 2-deoxy-2-[F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014;20:215–219.
55. Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic inflammation
associated with atherosclerosis. Immunobiology. 2013;218:1376–1384.
56. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13:709–721.
57. Yang M, Zheng J, Miao Y, et al. Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation
and cardiac fibrosis. Arterioscler Thromb Vasc Biol. 2012;32:1675–1686.
58. Falkenham A, de Antueno R, Rosin N, et al. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol. 2015;185:927–942.
59. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV
-infected patients. J Infect Dis. 2011;204:1227–1236.
60. Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV
infection. AIDS. 2014;28:969–977.
61. Shikuma CM, Barbour JD, Ndhlovu LC, et al. Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-α levels predict the presence of coronary artery calcium in HIV
-infected individuals independent of traditional cardiovascular
risk factors. AIDS Res Hum Retroviruses. 2014;30:142–146.
62. Tawakol A, Lo J, Zanni MV, et al. Increased arterial inflammation
relates to high-risk coronary plaque morphology in HIV
-infected patients. J Acquir Immune Defic Syndr. 2014;66:164–171.
63. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV
-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200:984–990.
64. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362–380.
65. Jilek S, Jaquiéry E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol. 2010;9:264–272.
66. O'Leary DH, Polak JF, Kronmal RA, et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular
Health Study Collaborative Research Group. Stroke. 1996;27:224–231.
67. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol. 2002;90:18L–21L.
68. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima–media thickness and cardiovascular
events. N Engl J Med. 2011;365:213–221.
69. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151:478–487.
70. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular
Health Study Collaborative Research Group. N Engl J Med. 1999;340:14–22.
71. Volpe GE, Tang AM, Polak JF, et al. Progression of carotid intima-media thickness and coronary artery calcium over 6 Years in an HIV
-infected cohort. J Acquir Immune Defic Syndr. 2013;64:51–57.
72. Hsue PY, Ordovas K, Lee T, et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012;109:742–747.
73. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV
infection. Circulation. 2004;109:1603–1608.
74. Kelly KM, Tarwater PM, Karper JM, et al. Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS. 2012;26:815–823.
75. Yearley JH, Pearson C, Carville A, et al. SIV
-associated myocarditis: viral and Cellular correlates of inflammation
severity. AIDS Res Hum Retroviruses. 2006;22:529–540.
76. Silwa K, Carrington MJ, Becker A, et al. Contribution of the human immunodeficiency virus acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J. 2012;33:866–874.
77. Khunnawat C, Mukerji S, Havlichek D Jr, et al. Cardiovascular
manifestations in human immunodeficiency virus-infected patients. Am J Cardiol. 2008;102:635–642.
78. Cheruvu S, Holloway CJ. Cardiovascular
disease in human immunodeficiency virus. Intern Med J. 2014;44:315–324.
79. Frustaci A, Petrosillo N, Vizza D, et al. Myocardial and microvascular inflammation
/infection in patients with HIV
-associated pulmonary artery hypertension. AIDS. 2014;28:2541–2549.